This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Roche Won't Buy Alexion Because Deal Is Too Expensive

Again, at a lower price, it would be easier for Roche to take the plunge but not at the current Alexion price tag.

Jim might be right, but only if Roche does something foolish and out of character.

If Roche really wants to get into the orphan drug business, buying Vertex would be a better fit, in my opinion. Vertex is going to dominate the cystic fibrosis treatment market for the foreseeable future, which is as big a commercial opportunity, if not larger, than anything Alexion is working on. Plus, with Vertex, Roche could also bolster its sagging hepatitis C business. A Roche acquisition of Vertex might be just as expensive as buying Alexion, but from a strategic standpoint, the former makes more sense to me.

[I've already called for Vertex to buy <b>Sarepta Therapeutics</b> <span class=" TICKERFLAT">(<a href="/quote/SRPT.html">SRPT</a><a class=" arrow" href="/quote/SRPT.html"><span class=" tickerChange" id="story_SRPT"></span></a>)</span>, so maybe that deal should happen first, before Roche steps in. Yes, I know, I'm just dreaming.]

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
RHHBY $31.14 -0.35%
ALXN $136.46 -1.93%
BMRN $65.11 0.57%
SRPT $11.18 4.10%
VRTX $80.14 -2.27%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs